Deferoxamine inhibits TRAIL-mediated apoptosis via regulation of autophagy in human colon cancer cells

Moon,Ji-Hong; Jeong,Jae-Kyo; Park,Sang-Youel

doi:10.3892/or.2014.3676

Deferoxamine inhibits TRAIL-mediated apoptosis via regulation of autophagy in human colon cancer cells

Authors:
- Ji-Hong Moon
- Jae-Kyo Jeong
- Sang-Youel Park
View Affiliations

Affiliations: Biosafety Research Institute, College of Veterinary Medicine, Chonbuk National University, Jeonju, Jeonbuk 561-756, Republic of Korea
Published online on: December 18, 2014 https://doi.org/10.3892/or.2014.3676
Pages: 1171-1176

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deferoxamine (DFO), an iron chelator, has numerous clinical applications for patients presenting with iron overload in regards to the improvement in the quality of life and overall survival. In addition, experimental iron chelators have demonstrated potent anticancer properties. The present study investigated the effects of DFO on TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in colon cancer cells and and the mechanism involved. The experimental results showed that DFO treatment inhibited TRAIL-mediated cancer cell apoptosis by increasing Akt activation and decreasing caspase activation in human colon cancer cells. Furthermore, DFO treatment induced autophagy flux, and chloroquine, an autophagy inhibitor, blocked DFO-mediated inhibition of TRAIL-induced apoptosis. The present study demonstrated that DFO inhibited TRAIL-mediated tumor cell death via the autophagy pathway, and the results suggest that potent anticancer agent, DFO, can be an inhibitor against antitumor therapy including TRAIL protein.

View Figures

View References

1	Steller H: Mechanisms and genes of cellular suicide. Science. 267:1445–1449. 1995. View Article : Google Scholar : PubMed/NCBI
2	Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 11:121–139. 1992. View Article : Google Scholar : PubMed/NCBI
3	Zhang JY: Apoptosis-based anticancer drugs. Nat Rev Drug Discov. 1:101–102. 2002. View Article : Google Scholar : PubMed/NCBI
4	MacFarlane M: TRAIL-induced signalling and apoptosis. Toxicol Lett. 139:89–97. 2003. View Article : Google Scholar : PubMed/NCBI
5	Lieu PT, Heiskala M, Peterson PA and Yang Y: The roles of iron in health and disease. Mol Aspects Med. 22:1–87. 2001. View Article : Google Scholar : PubMed/NCBI
6	Toyokuni S: Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med. 20:553–566. 1996. View Article : Google Scholar : PubMed/NCBI
7	Nelson RL: Dietary iron and colorectal cancer risk. Free Radic Biol Med. 12:161–168. 1992. View Article : Google Scholar : PubMed/NCBI
8	Bedford MR, Ford SJ, Horniblow RD, Iqbal TH and Tselepis C: Iron chelation in the treatment of cancer: a new role for deferasirox? J Clin Pharmacol. 53:885–891. 2013. View Article : Google Scholar : PubMed/NCBI
9	Nurtjahja-Tjendraputra E, Fu D, Phang JM and Richardson DR: Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood. 109:4045–4054. 2007. View Article : Google Scholar : PubMed/NCBI
10	Fu D and Richardson DR: Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21^CIP1/WAF1 by iron depletion. Blood. 110:752–761. 2007. View Article : Google Scholar : PubMed/NCBI
11	Hershko C: Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol. 7:965–1000. 1994. View Article : Google Scholar : PubMed/NCBI
12	Olivieri NF and Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. Blood. 89:739–761. 1997.PubMed/NCBI
13	Yun Z, Maecker HL, Johnson RS and Giaccia AJ: Inhibition of PPARγ2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell. 2:331–341. 2002. View Article : Google Scholar : PubMed/NCBI
14	Nakayama K: Cellular signal transduction of the hypoxia response. J Biochem. 146:757–765. 2009. View Article : Google Scholar : PubMed/NCBI
15	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
16	Deter RL and De Duve C: Influence of glucagon, an inducer of cellular autophagy, on some physical properties of rat liver lysosomes. J Cell Biol. 33:437–449. 1967. View Article : Google Scholar : PubMed/NCBI
17	Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI
18	Boya P, González-Polo RA, Casares N, et al: Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol. 25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
19	Karantza-Wadsworth V, Patel S, Kravchuk O, et al: Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 21:1621–1635. 2007. View Article : Google Scholar : PubMed/NCBI
20	Degenhardt K, Mathew R, Beaudoin B, et al: Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 10:51–64. 2006. View Article : Google Scholar : PubMed/NCBI
21	Lum JJ, Bauer DE, Kong M, et al: Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 120:237–248. 2005. View Article : Google Scholar : PubMed/NCBI
22	Hu YL, DeLay M, Jahangiri A, et al: Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 72:1773–1783. 2012. View Article : Google Scholar : PubMed/NCBI
23	Chaudhari AA, Seol JW, Lee YJ, Seol DW and Park SY: Hypoxia protects articular chondrocytes from thapsigargin-induced apoptosis. Biochem Biophys Res Commun. 381:513–517. 2009. View Article : Google Scholar : PubMed/NCBI
24	Agarwal E, Brattain MG and Chowdhury S: Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
25	Degterev A, Boyce M and Yuan J: A decade of caspases. Oncogene. 22:8543–8567. 2003. View Article : Google Scholar : PubMed/NCBI
26	Rubinsztein DC, Cuervo AM, Ravikumar B, et al: In search of an ‘autophagomometer’. Autophagy. 5:585–589. 2009. View Article : Google Scholar : PubMed/NCBI
27	Matsumoto G, Wada K, Okuno M, Kurosawa M and Nukina N: Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins. Mol Cell. 44:279–289. 2011. View Article : Google Scholar : PubMed/NCBI
28	Kroemer G and Jäättelä M: Lysosomes and autophagy in cell death control. Nat Rev Cancer. 5:886–897. 2005. View Article : Google Scholar : PubMed/NCBI
29	Liu Y, Cui Y, Shi M, Zhang Q, Wang Q and Chen X: Deferoxamine promotes MDA-MB-231 cell migration and invasion through increased ROS-dependent HIF-1α accumulation. Cell Physiol Biochem. 33:1036–1046. 2014. View Article : Google Scholar
30	Bertout JA, Patel SA and Simon MC: The impact of O₂ availability on human cancer. Nat Rev Cancer. 8:967–975. 2008. View Article : Google Scholar : PubMed/NCBI
31	Mazure NM and Pouysségur J: Atypical BH3-domains of BNIP3 and BNIP3L lead to autophagy in hypoxia. Autophagy. 5:868–869. 2009. View Article : Google Scholar : PubMed/NCBI
32	Gustafsson AB and Gottlieb RA: Autophagy in ischemic heart disease. Circ Res. 104:150–158. 2009. View Article : Google Scholar : PubMed/NCBI
33	Wang K, Liu R, Li J, et al: Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1α-mediated signaling. Autophagy. 7:966–978. 2011. View Article : Google Scholar : PubMed/NCBI
34	White E and DiPaola RS: The double-edged sword of autophagy modulation in cancer. Clin Cancer Res. 15:5308–5316. 2009. View Article : Google Scholar : PubMed/NCBI
35	Glick D, Barth S and Macleod KF: Autophagy: cellular and molecular mechanisms. J Pathol. 221:3–12. 2010. View Article : Google Scholar : PubMed/NCBI
36	Mizushima N: Autophagy: process and function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar : PubMed/NCBI
37	Mizushima N, Yoshimori T and Levine B: Methods in mammalian autophagy research. Cell. 140:313–326. 2010. View Article : Google Scholar : PubMed/NCBI
38	Singh K, Sharma A, Mir MC, et al: Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin). Mol Cancer. 13:702014. View Article : Google Scholar : PubMed/NCBI
39	Park KJ, Lee SH, Kim TI, et al: A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res. 67:7327–7334. 2007. View Article : Google Scholar : PubMed/NCBI
40	Ikeda Y, Tajima S, Yoshida S, et al: Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function. Atherosclerosis. 215:339–347. 2011. View Article : Google Scholar : PubMed/NCBI